Exploratory Phase III Study of Paclitaxel and Cisplatin Versus Paclitaxel and Carboplatin in Advanced Ovarian Cancer

2000443 citationsJournal Article

Authors

Paclitaxel-carboplatin is a feasible regimen for outpatients with ovarian cancer and has a better toxicity profile than paclitaxel-cisplatin.

Good health and well-being

Published in: Journal of Clinical Oncology

Volume 18, Issue 17, pp. 3084-3092

Field-Weighted Citation Impact: 35.47